R&D From phase 1 to phase 3: Scaling radiopharmaceutical trials Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
News Blackstone buys into Pfizer's GLP-1 drug development Blackstone Life Sciences will provide up to $1.5bn in funding to Pfizer for the development of its once-monthly GLP-1 agonist berobenatide.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
